Subjects
Inclusion criteria for this study included the following: healthy subjects must be 18 years of age or older (including 18 years of age). Volunteers had a body mass index (BMI) of 19.0-26.0 kg/m2 (BMI = weight [kg]/height2[m2]) and weighed no less than 50 kg for men and 45 kg for women.
Exclusion criteria included: allergy to the study drug, smoking, alcohol abuse, and use of CYP-modifying drugs within 30 days before the trial; the presence of clinically significant abnormalities in the results of physical examination, vital sign monitoring, electrocardiogram examination, and laboratory tests including routine blood, urine, and blood biochemistry performed during the screening period, which was judged by the investigator to be clinically significant; the presence of clinically significant cardiovascular, hepatic, renal, endocrine digestive tract, hematological system, respiratory system, psychiatric abnormalities, or existing diseases of the above systems; those with positive hepatitis B surface antigen, or positive hepatitis C antibody, or positive syphilis spirochete antibody, or positive HIV antibody test. In addition, subjects must not have participated in another clinical study within 90 days before the start of this study. Before any study procedures, all participants provided written informed consent after being informed by the clinical investigator of the purpose, nature, procedures, and any risks of the study.